Can the CSL share price hit $300…again?

While S&P/ASX 200 shares are getting hammered right now, the CSL share price has some momentum and could break the $300 barrier this week.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price jumped 4.19% in yesterday's trade to close at $282.24 per share. Any gains are welcome at the moment as ASX shares find themselves in a bear market. But is this just a flash in the pan or can CSL shares push to the $300 mark again?

How has the CSL share price performed?

On a day where the S&P/ASX 200 Index (ASX: XJO) fell 5.62% lower, the CSL share price surged. Despite falling 8.79% lower in March, CSL is still the largest ASX 200 share by market cap. CSL is worth a whopping $128.15 billion right now.

The CSL share price last broke the $300 per share barrier back in January, but quickly fell below that mark in the coronavirus-induced crash. Investors have been spooked by the pandemic which has sent governments and central banks scrambling for action.

However, the Aussie pharma group hasn't been hit too hard. For context, some ASX 200 shares have lost more than 70% since the start of March in the rout. I'm hoping we start to see some positive momentum behind CSL particularly as a leading pharmaceutical company in the current environment.

Given the high numbers involved, the $300 mark would require a 6.29% gain in the CSL share price from yesterday's close. I'm hopeful, but not confident given the day to day volatility we're seeing in ASX shares.

Should you buy into CSL right now?

CSL certainly isn't the top of my buy list, nor is it what I'd consider a cheap ASX 200 share. However, I think the $128.15 billion valuation is based on strong R&D and a solid moat around the company's earnings. 

I see the CSL share price bouncing back above $300 when the pandemic passes. How much further it has to go, I really don't know. However, I think there will be some short-term pain and I'd be waiting to buy.

Markets are inherently forward-looking, so valuations should reflect current economic expectations. While the current sell-off is hard to swallow, things will get better. It's all about choosing good companies and buying at cheap prices for the long-term.

Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Telix share price hits record high on strong quarter and guidance upgrade

This market darling has continued to deliver stunning top line growth.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 66% in FY24, will Telix Pharmaceuticals shares continue?

After such an impressive run, has the trend exhausted?

Read more »

Man sleeping with a sleep apnoea mask on.
Healthcare Shares

Buy Resmed shares at 'attractive entry level' says top broker

Could this be the right entry point to own Resmed?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

CSL shares hit new 52-week high! What's next?

These ASX experts reckon CSL investors are still in for a treat.

Read more »

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,
Healthcare Shares

NIB shares rise as top broker calls the stock a buy

Is this stock a healthy opportunity?

Read more »

Man pointing at a blue rising share price graph.
Healthcare Shares

Why is the Nanosonics share price rocketing 10% today?

Investors are pleased with a big improvement in this company's performance.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why the ResMed share price tanked in FY 2024 and what to expect in FY 2025

Down 11% in FY 2024, is the ResMed share price poised for a big turnaround in FY 2025?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX healthcare stock rocketing 25% on Friday?

What is getting investors excited? Let's find out.

Read more »